Progressive methods in treatment
Gluten absorption can be prevented by sealing tight junctions with larazotide acetate;
research has begun on TG2 inhibition and modulation of the immune system, as well as blocking HLA-DQ2;
induction of gluten tolerance has been established using Nexvax2, a new peptide epitope immunotherapy based on the principle of desensitization therapy for allergic conditions
Of particular interest is the treatment of refractory celiac disease. According to a retrospective study, budesonide provided clinical remission and recovery in approximately 90% of both types of refractory celiac disease.
In addition to diet modification, a number of ongoing clinical studies have shown promising results in the treatment of celiac disease, but these require further study:
oral gluten-digesting enzyme supplements tested: Latiglutinase (IMGX-003 or ALV-003), AN-PEP (prolyl endopeptidases derived from Aspergillus niger) and STAN1 (microbial enzyme cocktail);